Passa al contenuto
Merck

Irbesartan: a review of its use in hypertension and diabetic nephropathy.

Drugs (2008-07-17)
Katherine F Croom, Greg L Plosker
ABSTRACT

Irbesartan (Aprovel, Avapro, Irbetan, Karvea), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension. It is also approved in some regions for the treatment of nephropathy in patients with hypertension and type 2 diabetes mellitus. In adults with essential hypertension, irbesartan is effective at reducing blood pressure (BP) over a 24-hour period with once-daily administration. Irbesartan also slows the progression of renal disease in hypertensive patients with type 2 diabetes, with this effect partly independent of its BP-lowering effect. In addition, irbesartan was generally well tolerated in clinical trials. Thus, irbesartan is a useful treatment option for patients with hypertension, including those with type 2 diabetes and nephropathy.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Irbesartan, ≥98% (HPLC), powder
SKU
Taglio della confezione
Disponibilità
Prezzo
Quantità
USP
Irbesartan, United States Pharmacopeia (USP) Reference Standard
SKU
Taglio della confezione
Disponibilità
Prezzo
Quantità
Irbesartan, European Pharmacopoeia (EP) Reference Standard
SKU
Taglio della confezione
Disponibilità
Prezzo
Quantità